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Summary: A solid-phase enzyme-immunoassay for the determination of the digitoxin concentration in human
serum (Enzymun-Test® Digitoxin) was developed, and subsequently evaluated in seven laboratories. The test
is based on the competition principle. Polystyrene tubes coated with anti-digitoxin antibodies (from sheep)
were used äs the solid phase. In the concentration ränge 10—40 g/l, the coefflcient of Variation for the
majority of laboratories was between 2 and 7%. The day-to-day precision only slightly differed from the
within-run precision. The measuring ränge was between 4 and 60 g/l. Enzymun-Test® Digitoxin showed
good agreement with three known methods for digitoxin determination. No influence on the values was
observed in lipaemic, uraemic and icteric samples, dysproteinaemia sera and in the presence of various
digoxin derivatives. The new enzyme-immunoassay pennits the practical and reliable determination of serum
digitoxin and is suited for use in routine analysis.
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Klinische Evaluierung eines neuen Digitoxin-Enzym-Immunoassay
Zusammenfassung: Zur Bestimmung der Digitoxin-Konzentration im Humanserum wurde ein Festphasen-
Enzymimmunoassay (Enzymun-Test® Digitoxin) entwickelt und in sieben Laboratorien evaluiert. Der Test
beruht auf dem Kompetitionsprinzip. Als Festphase werden mit Anti-Digitoxin-Antik rpern (Schaf) beschich-
tete Polystyrolr hrchen eingesetzt. Im Konzentrationsbereich von 10 bis 40 μg/l lagen die Variationskoeffizien-
ten der meisten Labors zwischen 2 und 7%. Die Pr zision von Tag zu Tag unterschied sich nur unwesentlich
von der innerhalb einer Serie. Der Me bereich erstreckte sich von 4 bis 60 μg/l. Enzymun-Test® Digitoxin
zeigte eine gute bereinstimmung mit drei bekannten Methoden zur Digitoxin-Bestimmung. In lip mischen,
ur mischen und ikterischen Proben, Dysprotein mie-Seren sowie bei verschiedenen Digoxin-Derivaten wurde
keine Beeinflussung der Werte beobachtet. Dieser neue Enzymimmunoassay gestattet eine sichere und
praktikable Bestimmung des Digitoxins im Serum und ist f r den Einsatz in der Routine geeignet.
Introduction
Provided that suitable sampling times and sampling
conditions are used, the determination of glycoside
concentrations in human serum provides useful Infor-
mation on the actual intake, the distribution and the
excretion of Digitalis glycosides. Digitoxin determina-
tions help on the one hand to avoid dangerous long
term effects resulting from the comparatively long
half-life of digitoxin (l, 2), and on the other hand
enable an improved assessment of severe intoxica-
tions (3,4).
Measurement of serum glycoside concentrations
yields only a limited amount of Information, however,
on the myocardial uptake of the glycoside and the
degree of receptor-binding of the glycoside and its
active metabolites, which in the final reckoning is
responsible for the action of digitalis. The validity of
the Information obtained from measurements of the
glycoside concentration can be further restricted by
additional unexpected and possibly rapidly changing
pathological conditions, e. g. renal failure, thyroid
gland dysfunctions and derangement of the electro-
lyte and water balance (3 — 6).
In addition to the already known immunoassays for
determining digitoxin in serum (6 — 9), a new enzyme-
immunoassay has recently been presented (10). The
investigation of this test (Enzymun-Text® Digitoxin)
in 7 laboratories is described here.
Methods and Materials
Test principle and test procedure for Enzymun-Test®
Digitoxin1)
Enzymun-Test® Digitoxin is an enzyme-immunosassay based
on the competition principle. The digitoxin from the serum
sample (20 μΐ) and the digitoxin conjugate (l ml, digitoxin
Commercially available:
Enzymun-Test® Digitoxin
Cat. No.: 759 333
Company: Boehringer Mannheim GmbH
coupled with peroxidase from horse-radish) compete for digi-
toxin antibodies attached to the inner wall of polystyrene tubes.
After a 30 min period of incubation at room temperature, the
non-bound digitoxin conjugate is removed by aspirating the
liquid followed by a washing step. A solution of diammonium
Zjl'-azino-bis-iS-ethyl-benzothioazoline-o-sulphonate)
(ABTS®) is then added, and after 30 min the coloration result-
ing from the wall-bound peroxidase activity is measured spec-
trometrically at 405 nm. The intensity of colour produced is
inversely proportional to the digitoxin concentratiqn. Evalu-
ation is carried out via a hyperbolic caiibratipn curve prepared
with the aid of 5 Standards. The composition of the reagents
is listed in table 1.
Tab. 1. Composition of the reagents used in Enzymun-Test®
Digitoxin (manufacturer's Information).
40 mmol/1
2.5 g/l
2.
3.
Binding reaction
Buffer
Phosphate buffer, pH = 6.8
Bovine serum albumin
Coated tubes
 Λ .
Wall-bound polyclonal digitoxin antibodies from sheep
serum, specificity: see table 4
Digitoxin-peroxidase conjugate
Peroxidase
Bovine serum albumin
Indicator reaction
Phosphate/citrate buffer, pH = 4.4
H2O2 (sodium perborate)
ABTS®
Standards
Digitoxin added to digitoxin-free human serum, lyophilised;
concentrations:
Ο jig/1, 7.5 ng/1, 15 μδ/1, 30 μ$/1, 60 μδ/1
approx. 30 U/1
100 mmol/1
3.2 mmol/1
1.9 mmol/1
4. Control serum
Digitoxin added to digitoxin-free human serum, lyophilised
Sample material and quality control
Human sera from normal donors and patients receiving digi-
toxin therapy were used for the investigations; fresh sera were
used for investigating within-series precision, linearity and
interference, whereas deep-frozen sera were used for investigat-
ing day-to-day precision and carrying out method compari-
sons. The control serum contained in the Enzymun-Test® Digi-
toxin pack was also analysed for quality control purposes. In
the method comparisons, the control sera recommended by the
respective manufacturers were used.
J. Clin. Chem. Clin. Biochem. / Vol. 24,1986 / No. 8
Hoffs mmer et al.r Clinical evaluation of a new digitoxin enzyme-immunoassay 591
Participants, reagents and equipment
The laboratories taking part in the study are designated with
the letters A to G. Results from the Boehringer Mannheim
laboratories have been given the letter H. The order of appear-
ance of the authors' names on the title page of this paper does
not correspond to the sequence A to G.
Table 2 provides an overview of the comparison methods,
equipment and test variants.
2. In order to ascertain the lower detection limit, the zero
Standard was measured 30 times manually (without stop
reagent) and with the ES 22. In accordance with the defini-
tion by Kaiser (11), the lower detection limit was calculated
from the difference in measured Signals between the mean
and 3 Standard deviations. The results obtained by that
procedure were checked by measuring specimens having
digitoxin concentrations near the lower detection limit
(n = 20, digitoxin Standards: 2 μg/l and 4 μg/l).
Tab. 2. Participants and their methods.
Laboratory Working instructions for
Enzymun-Test® Digitoxin
manual
A
B
C
D
E
F
G
H
without
x
χ
with stop
reagent
X
X
X
X
ES 22
χ
X
X
X
X
X
X
Com-
pari-
son
meth-
ods*
1
1,3
1,2
2
2,3
3
2
1,2
*1: RIA l
2: RIA 2
3: Fluorescence Polarisation immunoassay
3. Within the scope of a collaborative study, all of the partici-
pants determined three "unknown" human serura-based,
lyophilized specimens containing different digitoxin concen-
trations (duplicate measurements on different 10 days).
4. The specificity of the digitoxin antibody was checked with
the digitoxin-like compounds listed in table 4. The interfer-
ence of 43 commonly used drugs was investigated in vitro
using twice the toxic concentrations according to 1. c. (12).
Lipaemic, uraemic and icteric (up to 171 μηιοΐ/ΐ bilirubin)
sera were included in the method comparison studies with
the reagents named above.
In order to check the possibility of interference by haemo-
lysis, human serum containing 14 μg/l digitoxin was spiked
stepwise with haemolysate up to a final concentration of 20
g/l Hb.
The influence of various human sera with pathologically
altered protein concentrations (see tab. 3) was investigated
by a stepwise blending with a human serum having a high
digitoxin concentration.
For the method comparisons, two radioimmunoassays and a
fluorescence Polarisation immunoassay were used:
Coat-A-Count, 125I-Digitoxin (Diagnostic Products, Corp., Los
Angeles, Cal., USA), GammaCoat™, 125I-Digitoxin (Clinical
Assays, Cambridge, Mass., USA) and Abbott TDx-Digitoxin
(Abbott Laboratories, North Chicago, II., USA).
With the exception of one laboratory, all of the participants
used Enzymun-Test® Digitoxin in association with the Enzy-
mun-Test® System ES 22 (Boehringer Mannheim GmbH), here-
after referred to s ES 22. By combining a spectrometer (Pho-
tometer 4010), Computer (Epson HX-2 microcomputer/Inter-
face 4010) and a pipetting/wash Station, ES 22 enables the test
to be largely mechanised. Curve fitting is achieved by a cubic
spline Interpolation (15).
For the manual technique, four laboratories tested a reagent,
which c n be used to stop the development of colour in the
indicator reaction f Enzymun-Test® Digitoxin (Enzymun-
Test®-Stop Reagent, Cat. No.: 811 769, Boehringer Mannheim
GmbH).
This reagent contains catalase (= 150 kU/1) in an acetate buffer
(50 mmol/1, pH 5.5) and 5 g/l detergent. By adding 0.1 ml of
the stop reagent to l ml of Substrate buffer solution, the oxida-
tion of the chromogen ABTS® is interrupted, while at the same
time the coloured ABTS® radical is stabilised.
Evaluation protocol
l. Within-series (20 duplicate determinations) and between-day
(single values from 10 days) precision of Enzymun-Test
Digitoxin was measured in the concentration r nge from
10-40 ug/1.
Tab. 3. Characteristics of human sera from four patients with
dysproteinaemia. These sera were used to investigate
the influence of dysproteinaemia on Enzymun-Test®
Digitoxin (Laboratory E).
Patient
1
2
3
4
IgA
(g/0
15.30
0.85
3.19
0.42
IgM
(g/l)
1.23
92.00
39.20
0.65
IgG
(g/l)
19.70
8.02
6.02
35.90
Kappa/
Lambda
7.90
2.40
0.02
5. Method comparison studies in human sera were made to
investigate the degree of agreement between various test
versions of Enzymun-Test® Digitoxin (manual procedure
with/without stop reagent; ES 22-procedure).
6. The accuracy of Enzymun-Test® Digitoxin was investigated
in the following experiments:
— Recovery of digitoxin in a (digitoxin-free) human serum
after spiking with definite amounts of the 60 μg/l digi-
toxin Standard. Recovery was checked by visual inspec-
tion of the graphic presentation obtained by plotting
found concentrations s a function of dilution.
— Comparison studies with human sera covering a widc
r nge of concentrations with three other frequently used
tests (t b. 2).
Statistical evaluation was performcd according to the stan-
dardised principle component analysis (13, 14).
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Results and Discussion
Precision
Depending upon the concentration, the majority of
coefficients of Variation were between 2 and 7% with
the day-to-day scatter being only slightly higher than
within series (figs. l and 2). The test System hence
shows good precision in the central concentration
r nge from about 10 to 40 μg/l.
When the timing cycles are carefully observed, the
values measured manually show precision similar to
that obtained with the ES 22. The procedure is simpli-
fied by the stop reagent, which removes the need for
careful timing of spectrometric measurements.
Analytical r nge limits
In the determination of the lower detection limit
values between l and 2 μg/l were obtained, with
values down to l μg/l using the ES 22. Imprecision
studies in that concentration r nge yielded coeffi-
cients of Variation of 39% (2 μg/l) and 9% (4 μg/l).
Thus the diagnostically useful measuring r nge ex-
tends from 4 μg/l to 60 μg/l (highest Standard) digi-
toxin.
Collaborative study
The results of the collaborative, interlaboratory tri l
(tab. 4) show interlaboratory coefficients of Variation
of 4.6%, 5.6% and 6.9% for the three samples used.
These data document a good comparability of values
from one laboratory to another.
Specificity
The results shown in table 5 show that the wall-
bound digitoxin antibodies are highly specific (lab-
oratory H): The metabolites of digitoxin showed
cross-reactions of 80 to 100%, whereas all of the
digoxin derivatives showed cross-reactions of less
than 2%. Cross-reactions of 53% and 41% respec-
tively were shown by the alpha- and beta-forms of
10
c
o
o
>
c
OJ
5 2
10 20 30
Dig i - tox in [μς/l ]
40
Fig. l. Within-series precision; groups of 20 duplicate determU
nations in human sera having differing digitoxin con-
centrations
+ manual procedure
o ES 22
10
o
·*-
o
£ 4
θ 2
10 20 30
Digitoxin
40
Fig. 2. Day-to^day precision; singje values obtained on 10 days
from pqrtions pf frozen human serum with differing
digitoxin concentrations
4- manual procedure
o ES 22
Tab. 4. Results of the collaborative study; duplicate detennin tions carried out on 10 days (manual in 2 laboratories; with ES 22
in 6 laboratories)
*Lyophilised human serum spiked with digitoxin (approx. 10, 20, 40 μg/l)
Sample
1*
2* (control serum)
3*
Target value
(μ§/1)
20.6
—
Mean value
te/i)
11.7
20.5
41.0
Medi n
(μ§/1)
11.7
20.4
40.9
Extreme values
(μέ/1)
9.9-14.6
18.5-23.5 >t
36.7-46.2
Inter-laboratory
c efiicient f
Variation (%),
(n = 80)
6.9
4.6
5.6
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K-strophanthin. Since the simultaneous use of stro-
phanthin (intravenous) and digitoxin is unusual and
illogical, this high cross-reaction should not be seen
äs a disadvantage.
Tab. 5. Cross reactions, calculated on a weight basis (Labora-
tory H).
% Cross reaction:
50%interceptanalyte 100
Accuracy
The results obtained in the recovery experiment (fig.
3) show an excellent recovery of digitoxin in serum.
As can be seen in table 6, values for the test versions
of Enzymun-Test® Digitoxin, carried out on a manual
or partially automated basis, are in close agreement.
Results of the same quality were found in compari-
50% intercept cross-reacting substanee sons with test kits of other manufacturers (tab. 7).
l
«
i
1[
t ' ;
t;
1-
i
'Vf.
f
»
Analyte Concentration
of the
cross-reacting
substanee
for 50%
intercept
Digoxin 1000
ß-Methyldigoxin 1150
a- Acetyldigoxin 1 1 00
ß- Acetyldigoxin 1 275
Lanatoside C 1600
Digoxigenin 1050
Digoxigenin-mono-digitoxoside 850
Digoxigenin-bis-digitoxoside 1 050
Digitoxigenin 90
Digitoxigenin-mono-digitoxoside 1 5
Digitoxigenin-bis-digitoxoside 18.5
Prednisolone 100000
Spironolactone 100000
Canrenone 55000
Prednisone 100000
Progesterone 1 00000
Dihydrodigoxin 77000
Proscillaridin 470
k-Strophantin-ß 36
k-Strophantin-a 28
Cortisol 100000
g-Strophantin (Ouabain) 2500
Per-
cent
cross i
reac-
tion
60 '
1.5
1.3 ^
·? *13 2*,
1.5 .E
1.8 o
86^8 s
98
'
7
 2080.0 °
0.02
0.02
0.03
0.02
0.02
0.02
3.1
41.1
52.9
0.02 Fig. 3.
0.6
i
\\
0.2 O.A 0,6 0.8 1.0
Fraction of digitoxin -free serum
in -the digi toxin Standard
Recovery of digitoxin in human serum (Laboratory D).
The digitoxin Standard contained 60 g/l
Tab. 6. Comparison of the three working procedures/applications of Enzymun-Test® Digitoxin
j
1
}
Working Working Range
specification specification y tested
Manual ES 22 5-60
Manual manual/with 5—60
stop reagent
Manual/stop reagent ES 22 2-60
Manual/stop reagent ES 22 8-65
Tab. 7. Comparison of Enzymun-Test® Digitoxin with
Test Test y Range
Enzymtin- tested
Test® (Hg/l)
Digitoxin
RIA1 ' ES 22 7-55
RIA 1 manual 5-40
RIA 1 manual 5-60
RIA 2 ES 22 4-70
RIA 2 ES 22 5-65
Fluorescence Polarisation ES 22 5—60
immunoassay
Regression equation
y = -2.108 + 1.049x
y = 0.378 + 0.921
y = -1.658 + 1.075x
y = 0.055 + 0.945x
other methods
Regression equation
y = -1.545 + 1.155X
y = -0.413 + 1.185x
y = 2.078 + 0.921x
y = 3.255 -f 0.908x
y = -0.747 H- 0.991x
y = 0.295 + 1.049x
r
0.944
0.908
0.960
0.985
r
0.900
0.956
0.911
0.919
0.893
0.976
Paired
values
102
102
70
50
Paired
values
70
45
102
55
102
47
Mediän of Labo-
the relative ratory
differences
-4.6 H
-8.6 H
-2.9 A
-5.4 D
Mediän of Labo-
relative ratory
difTerences
7.8 A
14.1 C
- 0.1 H
2.4 E
- 6.3 H
3.3 B
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y=x
20 40 60
Digi toxin (RIA 1) [/ig/l]
Fig. 4. Comparison of Enzymun-Test® Digitoxin (y) with
RIA l (x) in 102 human sera (Laboratory H, statistieal
data in table 6)
A: icteric
no Information
lipaemic
uraemic
dysproteinaemia
0 20 40 60
Digitoxin (RIA2)^g/ l ]
Fig. 5. Comparison of Enzymun-Test® Digitoxin (y) with
RIA 2 (x) in 55 human sera (Laboratory E, statistieal
data in table 6)
Δ: uraemic samples
+ : no Information
*: haemolytic samples
o: containing digoxin
Two typical plots are shown in figures 4 and 5. As
part of the method comparisons, the use of plasma
was also investigated (laboratories C, E, F and G). It
was found here that irrespective of the anticoagulants
used, the values measured for digitoxin were about
10—20% higher than with serum; for this reasori
only serum is recommended s sample material.
Since a reference method for the measurement of
digitoxin in serum is not available, the accuracy of
this new enzyme-immunoassay could only be assessed
by recovery experiments and comparison studies with
established methods. These investigations indicate
that Enzymun-Test® Digitoxin exhibits the same ae-
curacy s accepted radioimmunoassays.
Interfering substances
No indications of possible interfering factors were
found in the method comparison studies in lipaemic,
uraemic and icteric (up to 171 μηαοΐ/ΐ bilirubin) sera
(figs. 4 and 5).
In the drug interference studies all recoveries were
between 90 and 110% in terms of the initial value
(tab. 8). The pharmaceuticals shown in table 8 should
not therefore lead to any method-mediated influence
on the values measured with Enzymun-Test® Digitox-
in.
Haemoglobin did not interfere up to the highest con-
centration tested (20 g/l, 'see fig. 6).
No interferences were observed in the investigations
of four human sera containing pathologically altered
protein concentrations. The results obtained with the
serum from patient 2 (see tab. 3) are shown in
figure 7.
Conclusions
These studies show that Enzymun-Test® Digitoxin
produces values for digitoxin that are largely free
from interference and which are in good agreement
with the results from other eommerci lly available
tests. This test is an alternative to radioimmunologi-
cal methods, and enables the reliable and simple
determin tion of digitoxin, also in smaller routine
laboratories.
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Tab. 8. Influence of pharmaceuticals, used at twice the toxic
concentration (12).
Duplicate determinations using the ES 22 (Laboratory
H).
Pharmaceuticals Recovery
of digitoxin
Acetylsalicylic acid 97.3
Ampicillin 97.1
Meglium salt of amidotrizoic acid 100.8
Ascorbic acid 99.7
Meglium salt of iodipamide 92.7
Glibenclamide 101.7
Carbochromen 102.6
Quinidine (bisulphate) 100.5
ChJoramphenicol 93.0
Chlordiazepoxide 93.0
Bezafibrate 99.3
Caffeine 104.5
Dextran (polyglucose) 97.9
Etnaverine 96.5
Furosemide 91.3
Gelatine 90.1
Indometacin 99.9
Methaqualone 97.6
Methyldopa 102.4
Nicotinic acid 102.0
Nitrofurantoin 96.0
Noramidopyrine-methane-sulphonic acid 96.8
Oxazepam 106.5
Oxyphenbutazone 105.9
Oxytetracycline 110.0
Paracetamol 103.7
Phenazopyridine 104.4
Phenobarbitone 104.4
Phenprocoumon 101.1
Phenytoin 108.1
Probenecid 106.8
Procaine 103.3
Pyridamol 108.1
Pyritinol 100.5
Sulphamethoxazole 106.5
Theophylline 107.3
Trimethoprim 102.8
Carbimazole 95.2
Methylthiouracil 103.6
Allopurinol 101.6
Bilirubin 100.3
Methotrexate 100.6
Dexamethasone 105.3
120
"100
8 80
4l
er
(100%)
8 12 16
Haemogiobin [g/l]
20
Fig. 6. Influence of haemolysis on Enzymun-Test® Digitoxin
carried out using the ES 22 (digitoxin content 14
30
20
O
10
0,3 0.5 0.7 1.0
Fraction of immunopathy se rumina serum
with high digitoxin concentration
Fig. 7. Influence of a monoclonal immunopathy serum fpatient
2 in table 3) on the linearity of Enzymun-Test® Digi-
toxin (Laboratory E)
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